Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned […]
By Heather Main The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop […]
It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and […]
Chalk up another exciting development for the stem cell and regenerative medicine field in 2014. It’s been a huge year. For the first time ever, an ES cell-based device has been transplanted into a Diabetic patient. ViaCyte working together with […]
All the recent high-profile papers that are having troubles are bumming me out. The latest example is the “Betatrophin” Diabetes paper from Harvard last year. Yesterday it was called into major doubt by a new Cell paper from a group led by Jesper Gromada at […]
Copyright © 2017 | Designwork by Tradesouthwest Top
